| H |
|
H1299R mutation results in retention of mutant factor V molecule in the Golgi complex: a possible novel type of quantitative defect
|
| Yamazaki T., Nicolaes G. A. F., Sorensen K. W., Dahlback B. |
| |
|
Haematologic factors potentially implicated in the pathophysiology of avascular necrosis of the femoral head (AVN): hypercoagulability as a cause of AVN
|
| Séguin C., Passariello A., Alonzo M.-L., Theodoropoulos J., Busque L., Harvey E. J., Kassis J. |
| |
|
Haemoglobin induces the production and release of matrix metalloproteinase-9 from human malignant cells
|
| Siddiqui F., Siddiqui T. F., Francis J. L. |
| |
|
Haemostasis in surgery: Is there a role of haemorrhage control with rVlla in patients with liver disease?
|
| Mirza D. |
| |
|
Haemostasis in surgery: Mechanism of action of rFVlla and the potential of control of massive haemorrhage in patients without a pre-existing coagulopathy
|
| Lawson J. |
| |
|
Haemostasis parameters and different forms of Ovarian Hyperstimulation Syndrome
|
| Ivanets T. Y., Fantchenko N. D., Ivanets N. V. |
| |
|
Haemostyptics agents and blood platelet functions
|
| Pecka M., Maly J., Slezáková E. |
| |
|
Hand computer and Internet for collection and presentation of patient diary data in a Nordic clinical multicenter safety surveillance study of ReFacto®
|
| Petrini P., Berntorp E., Glomstein A., Ingerslev J., Riikonen P., Scheibel E., Schulman S., Siimes M., Stigendal L. |
| |
|
Haplotype and tissue-specific control of interleukin-6 expression and the implications in athero-thrombotic disease
|
| Khwaja H.A., Terry C.F., Green F.R. |
| |
|
Harmonization of D-Dimer test results
|
| Meijer P., Haverkate F., Spannagl M. |
| |
|
Health care costs and clinical outcomes in patients on chronic oral anti-coagulation undergoing perioperative bridging with low-molecular-weight heparin vs. unfractionated heparin
|
| Spyropoulos A. C., Frost F. J., Hurley J. S., Roberts M. |
| |
|
Health-related quality of life in adults with hemophilia: the patient perspective
|
| Flood E., Szende A., Rentz A., Gorina E., Larson P., Bullinger M., Schramm W., Wasserman J., Leidy N. K. |
| |
|
Health-related quality-of-life assessment in the hemophilia population
|
| Bullinger M. |
| |
|
Heart disease among males with hemophilia
|
| Kulkarni R., Soucie M. J., Evatt B. L., Haemophilia Surveillance System and Project Investigator‡ |
| |
|
Heat shock treatment induces stress tolerance in platelets
|
| Maurer-Spurej E., Yeong S. H. |
| |
|
Hemophilia A gene therapy using the third-generation lentiviral vector – Mouse model
|
| Yamanouchi M., Naka H., Sakurai Y., Tanaka I., Shima M., Matsumura R., Sakata Y., Yoshioka A. |
| |
|
Hemophilia A: total correction in mice and partial correction in dogs with canine FVIII using a new AAV serotype
|
| Sarkar R., Tetreault R., Gao G. P., Wang L., Bell P., Chandler R., Nichols T. C., Wilson J. M., Kazazian H. H. |
| |
|
Hemophilia as a model for analysis of human germ-line mutagenesis: frequent mosacism and low male to female sex ratio for G:C®A:T nonCpG transitions and the first observation of a nucleotide bi-mutation are consistent with effects in early embryogenesis
|
| Sommer S., Li X., Halangoda A., Karlea A., Wen C. Y., Estaki B., Scaringell W. A. |
| |
|
Hemophilia care in the new millenium: a global perspective
|
| Schramm W. |
| |
|
Hemophilia care in the new millenium: cost versus benefit
|
| Blanchette V. |
| |
|
Hemophilia in pediatrics: clinical experience in a single hemophilia center
|
| Bizzoni L., Gentile M., Poggini L., Santoro C., Mazzucconi M. G., Bernasconi S. |
| |
|
Hemophilia patients and the assessment of thrombin generation in platelet-rich plasma and platelet-poor plasma
|
| Johannessen M., Sørensen B., Friedrich U., Ingerslev J. |
| |
|
Hemophilia: treatment options in the twenty-first century
|
| Mannucci P. M. |
| |
|
Hemorrhage into the right cerebella hemisphere in hemophiliac boy with factor VIII inhibitor
|
| Klukowska A., Laguna P., Brzewski M. |
| |
|
Hemostasis and inflammation in advanced heart failure and after successful heart transplantation
|
| Cugno M., Mari D., Meroni P. L., Gronda E., Vicari F., Frigerio M., Coppola R., Bottasso B., Gregorini L., Grossi A. |
| |
|
Hemostasis during first trimester of spontaneous pregnancy and pregnancy after IVF&ET
|
| Ivanets T. Y., Fantchenko N. D., Ivanets N. V. |
| |
|
Hemostatic balance on leukemic cells surface – role of TF and uPAR
|
| Nadir Y. |
| |
|
Hemostatic changes in laparoscopic and laparotomic gynecological surgery
|
| Rogolino A., Gori A. M., Cellai A. P., Alessandrello Liotta A., Coccia M. E., Bracco G. L., Comparetto C., Paniccia R., Pepe G., Abbate R., Prisco D. |
| |
|
Hemostatic effect of activated recombinant factor VII (rFVIIa) in liver disease: studies in an in vitro model
|
| Tonda R., Galán A. M., Pino M., Cirera I., Hernández M. R., Ordinas A., Escolar G. |
| |
|
Hemostatic effect of rFVIIa (NovoSeven®) in a mouse model of type 1 von Willebrand disease (VWD)
|
| Tranholm M., Kristensen A. T., Pyke C., Rojkjaer L. P., Rojkjaer R. |
| |
|
Hemostatic effect of three factor VIIa analogs in antibody-induced hemophilia A in mice
|
| Tranholm M., Kristensen A. T., Pyke C., Rojkjaer R., Persson E. |
| |
|
Hemostatic markers in nonrheumatic atrial fibrillation patients without anticoagulant therapy
|
| Marco P., Roldan V., Marin F., Garcia A., Climent V., Garcia-Herola A., Toral A., Sogorb F. |
| |
|
Hemostatic parameters in Brazilian asymptomatic carriers of Factor V Leiden, prothrombin (G20210A) and methylenetetrahydrofolate reductase (C677T) mutations
|
| Godoi L. C., Carvalho M. G., Fernandes A. P. S. M., Vieira L. M., Giumarães D. A. M., Lages G. F. G., Bragança W. F., Souza R. C. C., Abrão R. C. O., Dusse L. M. S. |
| |
|
Hemostatic risk factors, metabolic control, and microalbuminuria in diabetes mellitus type 1
|
| Gallistl S., Kreuzer C., Leschnik B., Muntean W., Borkenstein M. |
| |
|
Heparin cofactor II deficiency in mice
|
| Tollefsen D. |
| |
|
Heparin derived oligosaccharides are capable of passing through the blood brain barrier: experimental evidence in a rat model
|
| Ma Q., Dudas B., Florain-Kujawski M., Cornelli U., Hanin I., Fareed J. |
| |
|
Heparin induced thrombocytopenia
|
| Chong B. |
| |
|
Heparin Induced Thrombocytopenia as it relates to emergency room issues
|
| Francis J. |
| |
|
Heparin neutralising agents instigate the binding of heparin to live cells
|
| Gebska M., Heward J., Clutterbuck R., Kakkar V. V., Scully M. F. |
| |
|
Heparin releasable TFPI Is not depleted after repeated injections of tinzaparin at therapeutic dose for up to 30 days
|
| Gouin-Thibault I., Pautas E., Andreux J. P., Siguret V. |
| |
|
Heparinase I digestion of tinzaparin: a novel approach to neutralize the anti-coagulant and potential hemorrhagic effects of low molecular weight heparin
|
| Schultz C., Iqbal O., Hoppensteadt D., Ma Q., Tobu M., Florian-Kujawski M., Fareed D. |
| |
|
Heparin-induced anti-platelet antibodies in very low birth-weight infants
|
| Kumar P., Deddish R. B., Walenga J. M., Hoppensteadt D. A., Prechel M. M., Drenth A., Messmore H. L., Fareed J. |
| |
|
Heparin-induced thrombocytopenia (HIT) in neonates and very young children undergoing congenital cardiac surgery: a likely under-recognized complication with significant morbidity and mortality: report of 4 sequential cases
|
| Boshkov L. K., Ibsen L., Kirby A., Ungerleider R., Shen I. |
| |
|
Hereditary coagulation factor deficiencies in Korea
|
| Lee S. M., Choi E. J., Lee K. S., Ahn H. S. |
| |
|
Heritability of clotting factors and the prothrombotic state: results from a large thrombophilic pedigree of French Canadian descent with Type I protein C deficiency
|
| Vossen C., Hasstedt S. J., Rosendaal F. R., Bauer K. A., Broze G. J., Long G. L., Scott B. T., Callas P. W., Bovill E. G. |
| |
|
Heritability of plasma antiphospholipid antibodies
|
| Souto J., Borrell M., Buil A., Llobet D., Felices R., Forner R., Almasy L., Blangero J., Fontcuberta J. |
| |
|
Heterogeneous molecular pattern of Factor VII deficiency associated to cerebral hemorrhage
|
| Pinotti M., Ferraresi P., Vianello M., Etro D., Chauansumrit A., Sasanakul W., Mariani G., Bernardi F. |
| |
|
High affinity heparin binding proteins are exposed on the surface and microvesicles of TF bearing cells and diminish heparin-mediated anticoagulation
|
| Clutterbuck R., Heward J., Gebska M., Kakkar V. V., Scully M. |
| |
|
High dose of atorvastatin does not effect levels of plasma tissue factor in patients with coronary artery disease
|
| Bartok A., Steiner S., Seidinger D., Jetzl A., Minar E., Stefenelli T., Kopp C. W. |
| |
|
High frequency of combined genetic prothrombotic defects in young patients with ischemic stroke
|
| Pratnicka M., Lewandowski L., Lukasik M., Kolacz E., Czyz A., Kozubski W., Zawilska K., Czyz A. |
| |
|
High frequency of factor V Leiden and prothrombin G20210A mutations in Greek hemophiliacs
|
| Foka Z., Lambropoulos A. F., Georgopoulos C., Kotsis A., Makris P. E. |
| |
|
High levels of coagulation factors IX or XI: risk factors for pulmonary embolism?
|
| Ten Wolde M., Duffels M. G. J., Bank I., Bakhtiari K., Meijers J. C. M., Hutten B. A., Koopman M. M. W., Büller H. R. |
| |
|
High levels of factors VIII, IX and XI in patients with a thromboembolic event
|
| Duboscq C., Ceresetto J., Shanley C., Stemmelin G., Rabinovich O., Gutierrez M., Mendizabal G., Dotti C., Castedo G., Melgar M., Bullorsky E. |
| |
|
High levels of plasma markers of coagulation factor VIII:C and von Willebrand factor are independent risk determinants of pregnancy-associated venous thromboembolism
|
| Gerhardt A., Zotz R. B., Maruhn B., Scharf R. E. |
| |
|
High levels of plasma markers of coagulation factors (I, VIII:C, XI, XII), inflammation, and hyperhomocysteinemia are risk determinants of pre-eclampsia and HELLP syndrome
|
| Gerhardt A., Zotz R. B., Goecke T., Beckmann M. W., Bielfeld P., Bender H. G., Scharf R. E. |
| |
|
High plasma homocysteine concentrations in cerebrovascular patients with Fabry disease
|
| Gensini F., Fedi S., Brogi D., Buechner S., Giusti B., Sestini I., Martinelli F., Bandinelli R., Coppo M., Arnetoli G., Abbate R., Borsini W. |
| |
|
High prevalence of aspirin resistance in patients with a history of myocardial infarction
|
| Kottke-Marchant K., Murugesan G., Gerber C., Kaldus T., Cannata R., Goormastic M., Topol E. J. |
| |
|
High prevalence of aspirin resistance in patients with acute coronary syndromes
|
| Fuchs I., Frossard M., Zeiner A., Losert H., Matta M., Sieder A., Laggner A. N., Jilma B. |
| |
|
High prevalence of prothrombin G20210A mutation among patients with deep venous thrombosis in Lebanon
|
| Taher A., Abou Mourad Y., Khalil I., Abou-Merhi T., Shamseddine A., Bazarbachi A. |
| |
|
High resolution crystal structures of two variant fibrinogens suggest ‘B:b’ interactions are critical to normal polymerization
|
| Kostelansky M. S., Betts L., Bolliger-Stucki B., Lounes K. C., Gorkun O. V., Lord S. T. |
| |
|
High risk of cerebral-vein thrombosis in patients with hyperhomocysteinemia
|
| Battaglioli T., Martinelli I., Passamonti S. M., Mannucci P. M. |
| |
|
High-dose interferon-alpha induction treatment combined with ribavirin for chronic hepatitis C in congenital coagulation disorders. A randomized, double-blind, placebo-controlled clinical trial
|
| Meijer K., Kappers-Klunne M. C., Novakova I. R. O., Mauser-Bunschoten E. P., Koopman M. M. W., Voogt P. J., Leebeek F. W. G., Haagsma E. B., Smid W. M., Schirm J., Veeger N. J. G. M., Van Der Meer J. |
| |
|
Higher reticulated platelet counts and enhanced expression of P-selectin in patients with immune thrombocytopenic purpura compared to patients with myelodysplastic syndromes
|
| Van Kraaij M. G. J., Kok K. F., Pennings A., Verbruggen H. W., Novakova I. R. O. |
| |
|
High-level in vitro expression of protein S after modifications of protein S cDNA
|
| Rezende S. M., Razzari C., Simmonds R. E. |
| |
|
High-level transgene expression of lentivirus-transduced human endothelial cells
|
| Kruithof E. K. O., Liu J. W., Dunoyer-Geindre S., Fish R., Yang H., Polack B., Pernod G. |
| |
|
Hiruquant®, a new simple and quick assay for monitoring of hirudin therapy
|
| Landmann H., Piquet P. |
| |
|
HIT Type II a clinically heterogenous, hypercoagulable state: why promp intervention is critical
|
| Haas S. |
| |
|
HIT type II: diagnostic approches and current treatment concepts based on the pathogenesis of HIT - the European experience
|
| Greinacher A. |
| |
|
HIV associated thrombocytopenia: a 3-year trend analysis at the Johannesburg Hospital
|
| Munster M., Cassim N., Jacobson B. F. |
| |
|
HLA-DR and CD40 ligand expressing T-lymphocytes are increased in circulation in patients with idiopathic dilated cardiomyopathy
|
| Ueno A., Murasaki K., Kawana M., Tanoue K., Kasanuki H. |
| |
|
Home treatment of patients with hemophilia in Russia
|
| Plyusch O. P., Kopylov K. G., Lopatina E. G. |
| |
|
Home-automated telemanagement affects quality of life in patients on anti-coagulation therapy
|
| Finkelstein J., Khare R., Ansell J. |
| |
|
Homocysteine as a risk factor for cardiovascular disease and venous thrombosis
|
| Clarke R. |
| |
|
Homocysteine concentrations are associated with increased t-PA and PAI concentrations in smokers
|
| Peeters A. C. T. M., Van Den Berkmortel F. W. P. J., Novakova I. R. O., Den Heijer M. |
| |
|
Homocysteine lowering by B vitamins and the prevention of secondary deep-vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial
|
| Den Heijer M., Willems H. P. J., Blom H. J., Gerrits W. B. J., Cattaneo M., Eichinger S., Rosendaal F. R., Bos G. M. J. |
| |
|
Homocysteine plasma levels in primary biliary cirrhosis (PBC)
|
| Fedi S., Marcucci R., Paniccia R., Antonucci E., Manta R., Poli D., Coppo M., Biagini M. R., Surrenti C., Abbate R., Gensini G. F. |
| |
|
How factor VIIa works in hemophilia
|
| Butenas S., Brummel K. E., Bouchard B. A., Mann K. G. |
| |
|
How should we prevent VTE in medical patients?
|
| Leizorovicz A. |
| |
|
How should we treat VTE in cancer patients
|
| Levine M. |
| |
|
How to switch from thrombin inhibitors to oral anticoagulants
|
| Harder S. |
| |
|
How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration
|
| Zhou A. |
| |
|
HR2 haplotype (4070G-A (FV1299 His-Arg)) in Turkish thrombosis patients
|
| Akar N., Ulu A., Akar E., Yilmaz E. |
| |
|
Human antibody against CD11b inhibits platelet–leukocyte interaction under high shear
|
| Sachs U., Lin F., Bux J., Ruf A., Chavakis T., Santoso S. |
| |
|
Human blood platelets: RNA transcript profiling using microarray and serial analysis of gene expression
|
| Gnatenko D., Dunn J.J., Mccorkle S.R., Weissmann M.D., Perrotta P.L., Bahou W.F. |
| |
|
Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner
|
| Biro E., Sturk-Maquelin K. N., Vogel G. M. T., Meuleman D. G., Smit M. J., Hack C. E., Sturk A., Nieuwland R. |
| |
|
Human endothelial cell protein C receptor (EPCR) expression: role of proximal and distal 5'-gene regulatory elements
|
| Crawley J., Follows G. A., Cockerill P. N., Mollica L., Bonifer C., Simmonds R. E., Wells D. J., Lane D. A., Rance J. B. |
| |
|
Human endothelial cells synthesize Protein Z
|
| Vasse M., Denoyelle C., Litzler P. Y., Legrand E., Vannier J. P., Soria C. |
| |
|
Human factor IX expression in megakaryocytes derived from electrophorated human hematopoietic cells
|
| Dargaud Y., Rodriguez M. H., Enjolras N., Plantier J. L., Negrier C. |
| |
|
Human glycoprotein VI: identification and blockade of the collagen-binding surface
|
| Smethurst P. A., Joutsi-Korhonen L., O'Connor M. N., Jennings N. S., Wilson E., Garner S. F., Knight C. G., Harmer I. J., Dafforn T. R., Ijsseldijk M. J. W., De Groot P. G., Watkins N. A., Farndale R. W., Ouwehand W. H. |
| |
|
Human platelet microparticles shedding is independent of the Cdc42/Rac1/PAK Pathway
|
| Vidal C., Bouziane A., Picard F., Weber S., Fontenay M. |
| |
|
Human platelets generate thromboxane A2 upon interaction with immobilized fibrinogen without a requirement for adherence in a Syk-dependent manner
|
| Jin J., Tuluc M., Kunapuli S. |
| |
|
Human vitamin K-dependent Gas6 gene: exon–intron structure and identification of allelic variants
|
| Muñoz X., Amador-Arjona A., Sumoy L., Garcia de Frutos P., Sala N. |
| |
|
Human, conformation-specific, anti-GPIIb/IIIa (aIIbb3) single-chain antibodies generated by differential phage-display: a new generation of platelet inhibitors specific for the activated GPIIb/IIIa receptor?
|
| Schwarz M., Roettgen P., Little M., Ylaenne J., Bode C., Peter K. H. |
| |
|
Hypercoagulability in cerebrovascular disease (CD): factor V Leiden, prothrombin G20210A and MTHFR C677T mutations and polymorphism in the annexin V kozac sequence
|
| De Oña R., Llamas P., Meseguer E., Fernandez De Velasco J., Esheverria A., Rábano J., Vizcarra E., Román A., García De Yébenes J., Tomás J. F. |
| |
|
Hypercoagulability in inflammatory bowel disease
|
| Needham J., Mahmood A., Stallard L., Taylor J., Mainwaring C. J., Ramage J. |
| |
|
Hypercoagulability in sickle cell disease: increased monocyte tissue factor expression and increased erythrocyte microparticles expressing phosphatidyl serine
|
| Vasse M., Lahary A., Chevallier C., Blois S., Levesque H., Vannier J. P., Lenormand B. |
| |
|
Hypercoagulation and elevated blood pressure induced by phosphatidylserine/phosphatidylcholine microvesicles in pregnant mice can be suppressed by heparin and annexin V
|
| Kobayashi T., Kohei O., Yusuke M., Mika S., Ryota O., Motoi S., Naohiro K. |
| |
|
Hyperhomocysteinemia (HH) down regulates thrombin generation. FII:C, FXII:C and FX:C are down-regulated in HH while FVII:C is unaffected by HH
|
| Ebbesen L. S., Christiansen K., Ingerslev J. |
| |
|
Hyperhomocysteinemia and other thrombophilic factors in Italian patients with inflammatory bowel disease
|
| Silingardi M., Beltrami M., Fornaciari G., Iorio A., Ghirarduzzi A., D'Incà M., Negri E., Casali A., Morini L., Iori I. |
| |
|
Hyperhomocysteinemia as a risk factor for TIA and stroke in patients with AF
|
| Poli D., Antonucci E., Cecchi E., Betti I., Morettini A., Nozzoli C., Alterini B., Mugnaini C., Gensini G. F., Prisco D. |
| |
|
Hyperhomocysteinemia is associated with the progression of peripheral arterial disease in type 2 diabetic patients
|
| Ciccarone E., Di Castelnuovo A., Assanelli D., Archetti S., Salcuni N., Donati M. B., Capani F., Iacoviello L. |
| |
|
Hyperhomocysteinemia: risk factor or consequence of venous thrombosis?
|
| Den Heijer M., te pOele M., Blom H. J. |
| |
|
Hyperprothrombinemia is associated with enhanced TAFI-mediated inhibition of fibrinolysis
|
| Colucci M., Binetti B. M., Asti D., Tripodi A., Semeraro N. |
| |
|
Hypochlorous acid-oxidized LDL rapidly induces platelet aggregation in the presence of low levels of ADP, thrombin, epinephrine and chemokines
|
| Gear A. R. L., Coleman L., Polanowska-Grabowska R. |
| |
